Breaking News

Nokia Oyj (ADR) NOK Stock News

Nokia Oyj (ADR) (NYSE: NOK) is having an incredible start to the day in the market today, and for good reason. A long standing feud between the company and Apple (NASDAQ: AAPL) has come to an end in a very beneficial way. As can be expected, this led to excitement among investors and gains in the stock. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:33), NOK is trading at $6.58 per share after a gain of $0.36 per share or 5.88% thus far today.





NOK Settles With AAPL And Forms Collaboration Agreement

As mentioned above, Nokia is having a strong time in the market today after announcing that litigation between the company and Apple surrounding an intellectual property dispute has come to an end. The two parties have reached a settlement, and most importantly have agreed to a multi-year patent license.




According to the collaboration agreement, Apple will receive certain network infrastructure products and several services from NOK. As a result, AAPL will continue to carry NOK digital health products in the online store. Also, the two parties are in the process of exploring future collaboration opportunities surrounding digital health initiatives. Finally, both Nokia and Apple have agreed to regular summits between top executives to ensure that the relationship works effectively and to the benefit of not only both parties, but the customers of both parties. In a statement, Maria Varsellona, Chief Legal Officer at NOK had the following to offer…

This is a meaningful agreement between Nokia and Apple… It moves our relationship with Apple from being adversaries in court to business partners working for the benefit of our customers.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on both NOK and AAPL. In particular, we’re interested in following the collaboration and excited to see what the result of the collaboration becomes. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Fiat Chrysler Au Rg FCAU Stock News

Fiat Chrysler Au Rg (NYSE: FCAU) was having what appeared to be a strong day in the market early on. That is, until a Department of Justice announcement came stating that they will be filing a civil suit against the company. Of course, this led to fear, causing investors to offload shares and sending the stock downward. As is normally the case, our partners at Trade Ideas were the first to alert us to the declines. At the moment (11:10), FCAU is trading at $10.56 per share after a loss of $0.20 per share (1.86%) thus far today.





FCAU Drops On DOJ Civil Suit

As mentioned above, Fiat Chrysler is off to an incredibly rough time in the market today after the United States Department of Justice made a key announcement. The announcement was that the DOJ plans to file a civil suit against FCAU as early as tomorrow.




The Department of Justice has alleged that FCAU is using what is known as a “Defeat Device” in their diesel vehicles. This device is designed to defeat the diesel emissions tests that are required by many states while not actually meeting the standards of these tests. Of course, if this goes the wrong way, it could prove to be a massive expense for Fiat Chrysler, which is why the stock is falling.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on FCAU. In particular, we’re interested in following the suit that is expected to be filed against the company tomorrow and digging in to see what the suit entails. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Gevo, Inc. GEVO Stock News

Gevo, Inc. (NASDAQ: GEVO) is off to a relatively strong day in the market today, and for good reason. Arizona’s Governor has cleared the company’s renewable fuel for road use. Of course, this led to excitement among investors, sending the stock upward and prompting an alert from our partners at Trade Ideas. At the moment (10:51), GEVO is trading at $0.88 per share after a gain of $0.03 per share (3.20%) thus far today.





GEVO Gains On Arizona Road Use Clearance

As mentioned above, Gevo is having a pretty strong day in the market today after announcing that a bill that was signed by Arizona Governor Doug Ducey will allow gas stations to sell isobutanol-blended gasoline for on-road use. This means that the company’s isobutanol blend will likely soon hit gas stations in the state, offering drivers higher performance through the use of renewable fuel content.




The bill, known as Bill HB2368, allows the use of isobutanol as an axygenate in gasoline, particularly for the use of on-road vehicles in Arizona. This law will take effect in August of this year. It will add to the demand for GEVO fuels, which are already being sold in Arizona for off-road applications including boating, ATV’s, motorcycles, landscaping equipment, and more. In a statement, Dr. Patrick Gruber, CEO at GEVO, had the following to offer:

We’re excited that this bill will open up a new market for our isobutanol in Arizona. With our distribution partner Musket already serving marinas, Gevo is ready to take advantage of this new opportunity to expand isobutanol sales in the state…”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on GEVO. In particular, we’re interested in following the news to see what happens to sales once isobutanol blends are able to be used in on-road applications. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 2779
CytRx Corporation CYTR Stock News

CytRx Corporation (NASDAQ: CYTR) is having a relatively rough start to the trading session today after yesterday’s run toward the top. After a run, we tend to see cold feet among investors, who push the stock down to a more reasonable price. That seems to be what’s happening now, which caused our partners at Trade Ideas to alert us to the losses. At the moment (10:24), CYTR is trading at $0.52 per share after a loss of $0.03 per share (5.60%) thus far today. Nonetheless, it’s probably not a bad idea if you’re considering buying this dip. In fact, there are two catalysts ahead in the short term.





CYTR Catalyst #1: June 2 – 6 Data Release

The first catalyst that’s coming surrounding CytRx Corporation is the release of clinical data. The company said it will soon be offering two abstract presentations at the 2017 American Society of Clinical Oncology Annual Meeting that will be taking place between June 2nd and June 6th. Of course, this could definitely move the stock, as positive clinical data generally does.

The first bit of data to be released comes from a key Phase 3 clinical trial. During the global trial, CYTR evaluated aldoxorubicin in comparison to the investigator’s choice in patients with relapsed and refractory soft tissue sarcomas (STS).




The second bit of data that the company plans to release surrounds a Phase 1 / 2 clinical trial. During this clinical trial, the company is combining aldoxorubicin with infosfamide/mesa (I-M). The treatment is designed as a first-line and second-line treatment for STS. In a statement with regard to the CYTR data release, Daniel Levitt, M.D., Ph.D., CEO and CMO at CytRx Corporation, had the following to offer:

The data from both of these important clinical trials evaluating aldoxorubicin in sarcomas, along with our several other completed clinical and preclinical studies, will form the basis of our planned New Drug Application submission to the U.S. Food and Drug Administration, and we are pleased to share these more mature and detailed results in this peer-reviewed forum with the medical and scientific communities.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

Catalyst 1 | Catalyst 2 | Next Page

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required









Helios and Matheson Analytics Inc HMNY Stock News

Helios and Matheson Analytics Inc (NASDAQ: HMNY) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced that it and RedZone have acquired global license rights to a key facial recognition software. Of course, this led to excitement among investors, causing gains in the stock and prompting our partners at Trade Ideas to alert us to the movement. At the moment (9:55), HMNY is trading at $4.00 per share after a gain of $1.55 per share or 63.27% thus far today.





HMNY Announces Acquisition

As mentioned above, Helios and Matheson Analytics is off to a great start in the market today after announcing that it and RedZone made a key acquisition. The two companies have acquired global license rights to IsItYou’s facial recognition technology in the field of crime and terrorism. The acquisition was acquired for integration with the RedZone Map product.

The goal of the acquisition is to integrate RedZone Map’s artificial intelligence technology and proprietary real-time crime database with the facial recognition technology. In doing so, HMNY and RedZone will allow RedZone Map users to identify people whose images they are able to capture through the smartphone’s camera. That is, if the image of the person is in the can be identified through the database within the RedZone Map.




This bodes well with RedZone’s plans on developing the ability to deliver real-time notifications of criminally active people within a given user’s area. In particular, this will be useful in large events and public spaces. However, to do so, the company will need to obtain permitted access to publicly located surveillance cameras operated by private enterprises as well as government entities.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

 1 | 2 | Next Page

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 687
EnteroMedics Inc ETRM Stock News

EnteroMedics Inc (NASDAQ: ETRM) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company has announced that it has acquired BarioSurg. This led to excitement among investors, causing gains and prompting our partners at Trade Ideas to alert us to the movement. At the moment (9:24), ETRM is trading at $6.07 per share after a gain of $1.48 per share or 32.24% thus far today.





ETRM Acquires BarioSurg

As mentioned above, EnteroMedics is having a strong day in the market today after announcing that it has acquired BarioSurg, Inc. BarioSurg is the investor of Gastric Vest, an investigational, minimally-invasive, laparoscopically implanted medical device. Lining up with the ETRM vBloc, Gastric Vest is designed to help treat morbid obesity.




The Gastric Vest device is wrapped around the stomach. Once there, it emulates the effect of conventional weight loss surgery. However, the treatment doesn’t permanently change the patient’s anatomy.

Gastric Vest is also proving to be effective. In fact, in a pilot study that was conducted out of the United States, patients that were treated with Gastric Vest demonstrated a mean percent excess weight loss of 85% after 12 months. This came with an average drop in HbA1c of 2.1 points as well as an average waist circumference reduction of 38 centimeters or approximately 15 inches.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

1 | 2 | Next Page

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1295
CytRx Corporation CYTR Stock News

CytRx Corporation (NASDAQ: CYTR) is off to a relatively strong day in the market today after announcing a coming annual meeting. This led to excitement among investors, pushing the value of the stock upward and prompting our partners at Trade Ideas to send the alert. At the moment (2:56), CYTR is trading at $0.54 per share after a gain of $0.02 per share or 4.14% thus far today.





CYTR Announces Coming Annual Meeting




As mentioned above, CytRx is having an incredibly strong day in the market today after releasing an SEC filing informing investors of a coming annual meeting. The company has invited investors to the 2017 Annual Meeting of Stockholders of CytRx Corporation. The meeting will be held on Wednesday, July 12, 2017 at 10:00 A.M. At the Hotel Bel Air in Los Angeles California. For complete details, see the filing here.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on CYTR. In particular, we’re interested in seeing the result of this annual meeting. We’re also interested in the coming data presentation that will take place between June 2nd and June 6th. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









GoPro Inc GPRO Stock News

GoPro Inc (NASDAQ: GPRO) is off to an incredibly strong day in the market today. Ultimately, the social crowd seems to be pointing to an outdated Seeking Alpha article as the reason for the gains. Nonetheless, our partners at Trade Ideas were the first to alert us to the movement. At the moment (12:47), GPRO is trading at $9.02 per share after a gain of $0.50 per share or 5.92%. However, if I had to make a bet, I would bet that these gains wouldn’t last long. Here’s why…





GPRO Doesn’t Offer Much

GoPro’s flagship product is an extreme action camera. I will admit that I own one of these cameras, and for all intensive purposes, it’s a great product. I attach the camera to my kayak and head down the rapids for great footage. However, think about how many people would actually want something like this.

Sure, there are quite a few people interested in extreme action sports, and even filming their own endeavors in this category. Nonetheless, this category is a very niche category. This means that on the grand scale, the audience that would actually be interested in buying the company’s flagship product is a relatively small one. After all, do you plan on strapping a GoPro to a kayak or a helmet and filming your endeavors any time soon? If you’re like most people, the answer is no!




The Company Is Desperately Lacking Innovation

When GoPro camera’s first came out, they were hotter than fire. They were the first thing that the world had seen that could do what they could do. However, as competition stepped into play, GPRO has simply failed to innovate. Sure, the company launched the Karma drone, but we all know where that’s going… down!

The bottom line is that a single solid product, while impressive in the short run, does very little for technology companies in the long run. At the end of the day, for GPRO to continue on an upward trend, it needs to be part of the latest and greatest in Tech. Unfortunately, they are failing miserably at doing so.

Want To See Something Ugly? Look At GoPro’s Balance Sheet

Another major issue for GPRO has to do with money itself. At first glance, things look pretty good. The company has about $75 million in their balance sheet and a credit facility that makes $82 million available upon request. Not to mention, a recent convertible debt offering that brought $92 million in. So, all in all, having $249 million to play with really doesn’t sound all that bad. That is, until you look into the company’s most recent performance.

In the last quarter, GPRO lost around $111 million. That’s a big chunk. If they do the exact same thing in the next two quarters to follow, they are going to go broke quickly. In fact, by the end of the third quarter, the company will be reaching for shoestrings, hoping that one has money on the end of it. At the end of the day, the data shows that the company is running out of money quickly. Sure, they could do another offering at the expense of investors, or even borrow more money, once again at the expense of investors. However, whatever they do, it’s going to be at the expense of investors.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

The Bottom Line Here

At the end of the day, GPRO has created an incredible product. The problem is that the product is tailored to a very small percentage of the global population. Without further innovation and an ability to expand its audience, the company is likely to run out of money very soon. As a result, investors will likely realize the one thing no one wants to see in the market, diminishing returns!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 2597
MannKind Corporation MNKD Stock News

MannKind Corporation (NASDAQ: MNKD) is having an incredibly strong day in the market today, and for good reason. One Drop | Plus has been launched. Of course, we’ll get into why that’s a big deal in a minute. Nonetheless, this launch led to excitement among investors who pushed the stock upward. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (12:17), MNKD is trading at $1.32 per share after a gain of $0.19 per share (17.12%) thus far today.





MNKD Gains On Global One Drop Launch

One Drop is becoming a leader in diabetes management, and it’s happening quickly, ultimately benefiting not only the company, but MannKind as well. So far, the digital diabetes management platform has 200,000 users worldwide, and that number is expanding quickly.

Today, MNKD investors were excited to learn of the launch of One Drop | Plus. This is helping One Drop expand its offering in order to better meet the individual needs of people that struggle with pre-, type 1 and type 2 diabetes. The new product is now available in the United States and Europe.




This is overwhelmingly positive news for MNKD, as the company announced a planned collaboration with One Drop earlier this month. This collaboration will provide cost savings and customized coaching content and will lead to innovation with regard to packaging and exploration of a reusable Afrezza inhaler with integrated Bluetooth technology. So, the launch of yet another likely popular One Drop product means that Afrezza will be seen by more and more consumers. With regard to the launch, Jeff Dachis, CEO and Founder of One Drop, had the following to offer:

At One Drop, we are bringing evidence-based diabetes care into the 21st century with seamlessly integrated devices, a fully featured diabetes management app, data-driven insights, and ongoing one-on-one support from dedicated diabetes experts (likely including MNKD experts) – all right on your mobile phone… No one wants more ‘business as usual’ with yet another clunky device in a vinyl zippered case, expensive supplies, or impersonal, reactive, remote diabetes monitoring from a call center. People deserve much better.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MNKD. In particular, we’re interested in following the coming collaboration with One Drop and how this collaboration turns into a profitable opportunity for the company. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Sorl Auto Parts, Inc. SORL Stock News

Sorl Auto Parts, Inc. (NASDAQ: SORL) is having an incredibly strong day in the mSarket today, and for good reason. The stock was featured in Zacks highlights with an incredibly high rank. This led to excitement among investors, sending the stock skyward and prompting an alert from our friends at Trade Ideas. At the moment (12:04), SORL is trading at $9.12 per share after a gain of $1.99 per share or 27.91% thus far today.





Zacks Highlights SORL

As mentioned above, SORL Auto Parts is having a strong day in the market after Zacks made the decision to inform investors of the stock in a feature. In their feature, Zacks pointed out several stocks that could be strong buying opportunities.




In the snippet with regard to SORL, Zacks pointed out that it has ranked the stock a #1, reminding investors that the stock has delivered an average positive earnings surprise of 94.5% over the past 4 quarters. Here’s the highlight that Zacks offered…

SORL Auto Parts, Inc. (NASDAQ: SORL – Free Report ) specializes in the development, production and distribution of air brake valves and hydraulic brake valves. This Zacks Rank #1 stock delivered an average positive earnings surprise of 94.5% in the trailing four quarters.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SORL. In particular, we’re interested in seeing if the company can continue the trend of positive earnings surprises that we have seen throughout the past year. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 6573
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...